Menter Alan, Gelfand Joel M, Connor Cody, Armstrong April W, Cordoro Kelly M, Davis Dawn M R, Elewski Boni E, Gordon Kenneth B, Gottlieb Alice B, Kaplan Daniel H, Kavanaugh Arthur, Kiselica Matthew, Kivelevitch Dario, Korman Neil J, Kroshinsky Daniela, Lebwohl Mark, Leonardi Craig L, Lichten Jason, Lim Henry W, Mehta Nehal N, Paller Amy S, Parra Sylvia L, Pathy Arun L, Prater Elizabeth Farley, Rahimi Robert S, Rupani Reena N, Siegel Michael, Stoff Benjamin, Strober Bruce E, Tapper Elliot B, Wong Emily B, Wu Jashin J, Hariharan Vidhya, Elmets Craig A
Baylor Scott and White, Dallas, Texas.
University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
J Am Acad Dermatol. 2020 Jun;82(6):1445-1486. doi: 10.1016/j.jaad.2020.02.044. Epub 2020 Feb 28.
Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 2% of the world's population. In this guideline, we focus the discussion on systemic, nonbiologic medications for the treatment of this disease. We provide detailed discussion of efficacy and safety for the most commonly used medications, including methotrexate, cyclosporine, and acitretin, and provide recommendations to assist prescribers in initiating and managing patients on these treatments. Additionally, we discuss newer therapies, including tofacitinib and apremilast, and briefly touch on a number of other medications, including fumaric acid esters (used outside the United States) and therapies that are no longer widely used for the treatment of psoriasis (ie, hydroxyurea, leflunomide, mycophenolate mofetil, thioguanine, and tacrolimus).
银屑病是一种涉及多个器官系统的慢性炎症性疾病，影响着全球约2%的人口。在本指南中，我们将讨论重点放在用于治疗该疾病的全身性非生物制剂上。我们对最常用药物（包括甲氨蝶呤、环孢素和阿维A）的疗效和安全性进行了详细讨论，并提供建议以帮助开处方者启动和管理接受这些治疗的患者。此外，我们还讨论了新型疗法，包括托法替布和阿普米拉斯，并简要提及了其他一些药物，包括富马酸酯（在美国以外使用）以及不再广泛用于治疗银屑病的疗法（即羟基脲、来氟米特、霉酚酸酯、硫鸟嘌呤和他克莫司）。
